{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:32:04Z","timestamp":1777386724093,"version":"3.51.4"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Boehringer Ingelheim"},{"name":"Tanabe-Mitsubishi"},{"name":"Kowa"},{"name":"Actelion"},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science KAKENHI","doi-asserted-by":"publisher","award":["16K09517"],"award-info":[{"award-number":["16K09517"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science KAKENHI","doi-asserted-by":"publisher","award":["16H05299"],"award-info":[{"award-number":["16H05299"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science KAKENHI","doi-asserted-by":"publisher","award":["26248050"],"award-info":[{"award-number":["26248050"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fugaku Trust for Medical Research"},{"name":"Vehicle Racing Commemorative Foundation"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.atherosclerosis.2018.05.053","type":"journal-article","created":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T05:31:50Z","timestamp":1527744710000},"page":"124-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Ticagrelor, a P2Y12 antagonist, attenuates vascular dysfunction and inhibits atherogenesis in apolipoprotein-E-deficient mice"],"prefix":"10.1016","volume":"275","author":[{"given":"Byambasuren","family":"Ganbaatar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiju","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hotimah Masdan","family":"Salim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachiko","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimie","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasutomi","family":"Higashikuni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichiro","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shusuke","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Soeki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Sata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib1","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2007.02.013","volume":"50","author":"Anderson","year":"2007","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1586\/erc.09.172","article-title":"Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist","volume":"8","author":"Capodanno","year":"2010","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib3","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib4","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib5","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1182\/blood-2010-08-263111","article-title":"The platelet P2Y(1)(2) receptor for adenosine diphosphate: congenital and drug-induced defects","volume":"117","author":"Cattaneo","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib6","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1111\/j.1538-7836.2012.04894.x","article-title":"Increased platelet activation and thrombosis in transgenic mice expressing constitutively active P2Y12","volume":"10","author":"Zhang","year":"2012","journal-title":"J.\u00a0Thromb. Haemostasis"},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s11239-006-9033-4","article-title":"Nicotine upregulates the expression of P2Y12 on vascular cells and megakaryoblasts","volume":"22","author":"Shanker","year":"2006","journal-title":"J.\u00a0Thromb. Thrombolysis"},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib8","doi-asserted-by":"crossref","first-page":"31390","DOI":"10.1074\/jbc.M110714200","article-title":"Characterization and channel coupling of the P2Y(12) nucleotide receptor of brain capillary endothelial cells","volume":"277","author":"Simon","year":"2002","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib9","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1161\/01.ATV.0000142376.30582.ed","article-title":"ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels","volume":"24","author":"Wihlborg","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib10","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1161\/ATVBAHA.116.308725","article-title":"P2Y12 promotes migration of vascular smooth muscle cells through cofilin dephosphorylation during atherogenesis","volume":"37","author":"Niu","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib11","doi-asserted-by":"crossref","first-page":"H853","DOI":"10.1152\/ajpheart.00862.2013","article-title":"Involvement of P2Y12 receptor in vascular smooth muscle inflammatory changes via MCP-1 upregulation and monocyte adhesion","volume":"308","author":"Satonaka","year":"2015","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1471-2172-5-16","article-title":"P2 receptor mRNA expression profiles in human lymphocytes, monocytes and CD34+ stem and progenitor cells","volume":"5","author":"Wang","year":"2004","journal-title":"BMC Immunol."},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib13","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/cvr\/cvu108","article-title":"Purinergic receptors and atherosclerosis: emerging role for vessel wall P2Y12","volume":"102","author":"Rauch","year":"2014","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib14","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1161\/ATVBAHA.111.239095","article-title":"Roles of purinergic receptor P2Y, G protein-coupled 12 in the development of atherosclerosis in apolipoprotein E-deficient mice","volume":"32","author":"Li","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib15","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/cvr\/cvu028","article-title":"Vessel wall, not platelet, P2Y12 potentiates early atherogenesis","volume":"102","author":"West","year":"2014","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib16","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1161\/ATVBAHA.110.213702","article-title":"Regulation of functionally active P2Y12 ADP receptors by thrombin in human smooth muscle cells and the presence of P2Y12 in carotid artery lesions","volume":"30","author":"Rauch","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib17","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1160\/TH16-12-0973","article-title":"Biological effects of ticagrelor over clopidogrel in patients with stable coronary artery disease and chronic obstructive pulmonary disease","volume":"117","author":"Campo","year":"2017","journal-title":"Thromb. Haemostasis"},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib18","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1016\/j.jacc.2017.02.048","article-title":"Effect of ticagrelor versus clopidogrel on vascular reactivity","volume":"69","author":"Alemayehu","year":"2017","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib19","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1161\/01.ATV.0000225288.74170.dc","article-title":"Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects","volume":"26","author":"Heitzer","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib20","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.atherosclerosis.2006.12.009","article-title":"A\u00a0single loading dose of clopidogrel causes dose-dependent improvement of endothelial dysfunction in patients with stable coronary artery disease: results of a double-blind, randomized study","volume":"196","author":"Warnholtz","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib21","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.mvr.2009.01.009","article-title":"Clopidogrel attenuates atheroma formation and induces a stable plaque phenotype in apolipoprotein E knockout mice","volume":"77","author":"Afek","year":"2009","journal-title":"Microvasc. Res."},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib22","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.2147\/DDDT.S105718","article-title":"Ticagrelor promotes atherosclerotic plaque stability in a mouse model of advanced atherosclerosis","volume":"10","author":"Preusch","year":"2016","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib23","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1161\/01.ATV.0000051384.43104.FC","article-title":"Endothelial dysfunction: a marker of atherosclerotic risk","volume":"23","author":"Bonetti","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib24","doi-asserted-by":"crossref","first-page":"Iii27","DOI":"10.1161\/01.CIR.0000131515.03336.f8","article-title":"Role of endothelial dysfunction in atherosclerosis","volume":"109","author":"Davignon","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib25","first-page":"355","article-title":"Histologic, hematologic, and biochemical characteristics of apo E-deficient mice: effects of dietary cholesterol and phytosterols","volume":"79","author":"Moghadasian","year":"1999","journal-title":"Lab. Invest."},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib26","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.atherosclerosis.2015.03.023","article-title":"Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice","volume":"242","author":"Hara","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib27","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.vph.2015.08.011","article-title":"Dipeptidyl peptidase-4 inhibitor, linagliptin, ameliorates endothelial dysfunction and atherogenesis in normoglycemic apolipoprotein-E deficient mice","volume":"79","author":"Salim","year":"2016","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib28","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"Hansson","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib29","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nature01323","article-title":"Inflammation in atherosclerosis","volume":"420","author":"Libby","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1083\/jcb.201412052","article-title":"Recent insights into the cellular biology of atherosclerosis","volume":"209","author":"Tabas","year":"2015","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib31","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.clpt.2005.08.002","article-title":"Anti-inflammatory effects of clopidogrel intake in renal transplant patients: effects on platelet-leukocyte interactions, platelet CD40 ligand expression, and proinflammatory biomarkers","volume":"78","author":"Graff","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib32","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nrd1132","article-title":"Targeting JNK for therapeutic benefit: from junk to gold?","volume":"2","author":"Manning","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib33","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2004-05-1868","article-title":"NADPH oxidase mediates vascular endothelial cadherin phosphorylation and endothelial dysfunction","volume":"104","author":"Nwariaku","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib34","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1161\/CIRCRESAHA.107.165795","article-title":"ADP stimulates human endothelial cell migration via P2Y1 nucleotide receptor-mediated mitogen-activated protein kinase pathways","volume":"102","author":"Shen","year":"2008","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib35","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1113\/jphysiol.1984.sp015385","article-title":"Source and concentration of extracellular adenosine triphosphate during haemostasis in rats, rabbits and man","volume":"354","author":"Born","year":"1984","journal-title":"J.\u00a0Physiol."},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib36","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1002\/jcp.24568","article-title":"Adenosine regulates the proinflammatory signaling function of thrombin in endothelial cells","volume":"229","author":"Hassanian","year":"2014","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.imlet.2005.04.005","article-title":"Adenosine receptors and the control of endothelial cell function in inflammatory disease","volume":"101","author":"Sands","year":"2005","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib38","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/j.jacc.2016.02.023","article-title":"Ticagrelor improves peripheral arterial function in acute coronary syndrome patients: relationship with adenosine plasma level","volume":"67","author":"Fromonot","year":"2016","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib39","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/bph.13429","article-title":"Effects of P2Y12 receptor antagonists beyond platelet inhibition\u2013comparison of ticagrelor with thienopyridines","volume":"173","author":"Nylander","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib40","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1161\/CIRCULATIONAHA.116.024014","article-title":"Protective effects of ticagrelor on myocardial injury after infarction","volume":"134","author":"Vilahur","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib41","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10557-017-6763-9","article-title":"Unraveling the interaction of aspirin, ticagrelor, and rosuvastatin on the progression of atherosclerosis and inflammation in diabetic mice","volume":"31","author":"Ye","year":"2017","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib42","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/clc.22575","article-title":"Similar impact of clopidogrel or ticagrelor on carotid atherosclerotic plaque inflammation","volume":"39","author":"Oh","year":"2016","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.05.053_bib43","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.jcin.2017.05.064","volume":"10","author":"Jeong","year":"2017","journal-title":"JACC Cardiovasc. Interv."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002191501830296X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002191501830296X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T17:38:15Z","timestamp":1568914695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002191501830296X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":43,"alternative-id":["S002191501830296X"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.05.053","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ticagrelor, a P2Y12 antagonist, attenuates vascular dysfunction and inhibits atherogenesis in apolipoprotein-E-deficient mice","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.05.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}